# Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)

> **NCT05112549** · PHASE1 · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 46 (estimated)

## Conditions studied

- Leptomeningeal Disease

## Interventions

- **DRUG:** Nivolumab [Opdivo]

## Key facts

- **NCT ID:** NCT05112549
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-12
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112549, "Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05112549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*